-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

Benzinga·10/12/2026 13:20:15
Listen to the news
UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $14.